Mejora de la calidad de vida de los pacientes con urticaria crónica espontánea tratados con omalizumab en vida real

There was a very good response in T1, which was maintained in T6 and T12. Patients with chronic urticaria treated with omalizumab presented good results with a reduction of CUE activity and improvement of their QOL.